GLOBAL CHOLERA VACCINES MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Global    Analysis & Forecast: 2025-2032

Global Cholera Vaccines Market is estimated to be valued at USD 82.7 Mn in 2025 and is expected to reach USD 185.1 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 12.2% from 2025 to 2032.

Key Takeaways

• According to product type, the Vaxchora category is anticipated to account for 31.5% of the Global Cholera Vaccines market in 2025.
• Regionally, North America holds the largest market share of 37.1% for global cholera vaccines market growth by 2025.

Market Overview

The Global cholera vaccines Market Size is experiencing robust growth, which is driven by increasing cholera outbreaks, heightened awareness, and supportive government and international initiatives. Cholera vaccines market is set for significant growth proppeled by rising disease incidence, strong public health initiatives, and advances in vaccine technology. The market remains dominated by oral vaccines, with Dukoral as the leading product, and is expected to expand further as awareness and access improve globally.

For instance, April 2024, A new oral vaccine for cholera has received prequalification by the World Health Organization (WHO) on 12 April. The inactivated oral vaccine Euvichol-S has a similar efficacy to existing vaccines but a simplified formulation, allowing opportunities to rapidly increase production capacity.

Current Events and Its Impact on the Global Cholera Vaccines Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

AI in the Global Cholera Vaccines Market

AI is playing an increasingly influential role in the global cholera vaccines market which impacts multiple facets from vaccine development to outbreak management and supply chain optimization. In vaccine research and development, AI and machine learning (ML) are used to accelerate antigen selection, epitope prediction, and adjuvant identification enabling more effective and targeted vaccine formulations while reducing the reliance on traditional trail-and-error approaches.   

Government Regulations

• In the U.S., the FDA is responsible for approving cholera vaccines, with Vaxchora being the only vaccine licensed for use. The FDA initially approved Vaxchora for adults aged 18-64 travelling to cholera affected areas, later expanding its use to include children and adolescents aged 2-17 years.
• The Centers for Disease Control and Prevention (CDC) and its Advisory Committee on Immunization Practices (ACIP) recommend Vaxchora for travelers aged 2-64 years visiting regions with active cholera transmission, and provide detailed guidelines for pretravel consultations and vaccine administration.
• The WHO (World Health Organization) plays a central regulatory and prequalification role approving oral cholera vaccines such as Shanchol, Euvichol, and Euvichol-plus for use in international immunization programs and outbreak response. These vaccines are not available in the U.S. but are widely used in other regions, especially in mass vaccination campaigns coordinated by governments and international agencies.

Segmental Insights

To learn more about this report, Download Free Sample

Global Cholera Vaccines Market Insights, by Product type

In terms of product type, the Vaxchora segment is expected to contribute 31.5% share of the Global Cholera Vaccines market trends in 2025. Unlike other cholera vaccines, Vaxchora is the only vaccine approved by the U.S. FDA and is specifically recommended for travelers aged 2 to 64 years visiting regions with high cholera transmission. Its appeal is driven by the rising number of international travelers and the need for rapid, effective protection, as Vaxchora offers high efficacy 90.3% after 10 days and 79.5% after three months of administration.

Global Cholera Vaccines Market Insights, by Vaccine Type

In terms of product type, the Vaxchora segment is expected to contribute largest share of the Global Cholera Vaccines market trends in 2025. These vaccines represent the largest and most dominant segment in the global cholera vaccines market. These vaccines, such as Dukoral combines inactivated Vibrio cholerae O1 strains with a recombinantly produced B subunit of cholera toxin which provides both systemic and mucosal immunity.   

Global Cholera Vaccines Market Insights by Patient Type -  Rising Popularity of International Surfing Tourists

In terms of product type, the pediatric segment is expected to contribute largest share of the Global Cholera Vaccines market trends in 2025. Government immunization initiatives, international support, and ongoing research to improve vaccine efficacy further enhane pediatric coverage, making this segment vital for controlling cholera outbreaks and reducing disease burden ammong children in high-risk areas.

Global Cholera Vaccines Market Insights, by Distribution Channel

In terms of product type, the public segment is expected to contribute largest share of the Global Cholera Vaccines market trends in 2025. The effectiveness of public vaccination drives can be challenged by factors like political instability, logistical hurdles, and the need for robust cold chain management particularly in remote or conflict affected areas. Overall, the public segment remains the primary force behind the expansion and impact of the global cholera vaccines market.  

Regional Insights

To learn more about this report, Download Free Sample

North America Global Cholera Vaccines Market

North America has historically been the dominant region as it drives major Global Cholera Vaccines Market Trends. Furthermore, it is projected to hold a 37.1% market share in 2025, as this region benefits from state-of-the-art research and development facilities, robust healthcare systems, and efficient distribution networks, ensuring widespread vaccine availability and administration.

Europe Global Cholera Vaccines Market

Europe is considered to be the second largest region for Global Cholera Vaccines Market as it is driven by increasing international travel, heightened awareness of cholera prevention, and supportive regulatory frameworks that facilitate vaccine approvals and access. European demand is primarily fueled by travelers to cholera-endemic regions with oral cholera vaccines which are being the most widely used due to their established efficacy and stockpiling by organizations such a the WHO.  

Global Cholera Vaccines Market Dominating Countries

U.S Cholera Vaccines Market

The market in the U.S. is primarily driven by the presence and exclusive approval of Vaxchora, the only cholera vaccine licensed by the U.S. FDA for use among travelers aged from 2-4 years visiting cholera endemic areas. The rising trend of international travel from U.S., coupled with heightened awareness of preventive health measures has fueled demand for cholera vaccination, especially for travel-related purposes.

India Cholera Vaccines Market

India is a pivotal player in the global cholera vaccines market, both as a high burden country and as the world’s largest vaccine manufacturer and exporter, supplying approx. 60% of global vaccine demand. The country faces persistent cholera outbreaks due to challenges in water sanitation and hygiene, particularly in densely populated and rural areas, making cholera vaccination a public health priority.

Market Report Scope

Global Cholera Vaccines Market: Growth Drivers

• Increasing Vaccination Campaigns: Increasing vaccination campaigns by healthcare organizations such as the World Health Organization (WHO) and the United Nations Children’s Fund (UNICEF) are expected to drive the global cholera vaccines market over the forecast period.
• For instance, on March 8, 2025, the World Health Organization (WHO) and the United Nations Children’s Fund (UNICEF), a humanitarian aid organization, in coordination with health authorities, the Syria Immunization Group (SIG), and the Global Alliance for Vaccines (GAVI), kicked off a cholera vaccination campaign in earthquake-hit areas of northwest Syria.
• Increasing Fundings and Investments: Increasing adoption of inorganic growth strategies such as fundings and investments is expected to drive the global cholera vaccines market. For instance, In July 2022, the U.S. Agency for International Development (USAID) provided nearly US$ 1,180 million surge in humanitarian assistance that allowed USAID partners to provide critical aid for millions of people across the region.

Global Cholera Vaccines Market: Trends

• Growth in research funding and grants: Increasing adoption of inorganic growth strategies such as funding and grants is expected to drive the global cholera vaccines market over the forecast period. 
• For instance, on January 25, 2023, the International Federation of Red Cross’s (IFRC) Disaster Response Emergency Fund approved a grant of nearly 500,000 Swiss francs to help the Mozambique Red Cross address a cholera outbreak that is affecting five provinces. The Red Cross is part of Mozambique’s national disaster management structure and the inter-agency humanitarian country team.

Global Cholera Vaccines Market: Opportunities

• Increasing Educational Training Programmes: Increasing educational training programs regarding cholera vaccine manufacturing is expected to drive market growth over the forecast period. According to the data provided by the International Vaccine Institute (IVI), in December 2022, the International Vaccine Institute (IVI) conducted on-site training and consultation for Afrigen Biologics & Vaccines (Afrigen) in South Africa to help strengthen the company’s manufacturing capacity as part of the GLOBAL TRAINING HUB FOR BIO MANUFACTURING (GTH-B) PROGRAM and was funded by the Korean Ministry Of Health And Welfare.
• The training led by a team of senior IVI scientists provided education on overall production, including vaccine technology transfer, manufacturing-related safety, quality management system, and good laboratory practice (GLP).
• Potential for Combination Vaccines: Potential for combination vaccines could provide a great opportunity in the global cholera vaccines market. As per the World Health Organization (WHO), combination vaccines help reduce the number of injections given to a child and may improve vaccination coverage rates. This approach carries significant benefits, especially in low and middle-income countries where immunization resources are often constrained.

Global Cholera Vaccines Market: Key Developments

• January 2025, The cholera outbreak was detected in the camp in early October and subsequently confirmed by laboratory tests. Because Al Hol does not have a specialist treatment centre for acute watery diarrhoea, it is crucial that as many people are vaccinated as quickly as possible, the UN Children’s Fund, UNICEF, insists.

• September 2024: As summer approaches in the Southern Hemisphere and mosquito-transmitted diseases peak, the Argentine Republic has announced plans to defeat the ongoing dengue virus outbreak.

• January 2024, the Government of Zimbabwe launched a vaccination campaign against cholera in collaboration with UNICEF and the World Health Organization (WHO). The first cholera vaccines were administered by the Health and Child Care Honorable Minister, Dr Douglas Mombeshora during an event in Kuwadzana.

Analyst Opinion

• Oral cholera vaccines (OCVs), including Dukoral, Shanchol, and Euvichol, are the most widely used, with Dukoral holding the largest market share in 202423.
• The Vaxchora segment is expected to grow at the highest CAGR, mainly due to increased international travel and its unique approval status in the U.S.
• Asia-Pacific leads the market in terms of share and is projected to grow at the fastest rate, supported by major vaccine manufacturers in India, China, and the Republic of Korea, as well as high disease prevalence and strong government initiatives.
• Favorable government policies, increased awareness, and robust immunization programs are key factors accelerating market growth globally.  

Market Segmentation

• By Product Type
  • Vaxchora
  • Dukoral
  • ShanChol
  • Euvichol-Plus/Euvichol
  • Others (Late Phase Vaccines, etc.)
• By Vaccine Type
  • Killed Whole-cell and Recombinant Cholera Toxin B Vaccine
  • Killed Whole-cell Only Vaccines
  • Live Attenuated Oral Cholera Vaccine
• By Patient Type
  • Pediatric
  • Adults
• By Distribution Channel
  • Public
  • Private
• By Region:
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Top Companies in the Global Cholera Vaccines Market:
  • Sanofi
  • Biovac.co.za.
  • EMERGENT
  • Celldex Therapeutics
  • Valneva SE
  • Hilleman Laboratories
  • Shanghai United Cell Biotechnology Co., Ltd (Hillhouse Capital)
  • PaxVax, Inc.
  • Astellas Pharma Inc.
  • EUBIOLOGICS CO., LTD.

Sources

• Primary Research interviews
  Valneva, Emergent BioSolutions, Shantha Biotechnics, EuBiologics, WHO, UNICEF, GAVI, Johns Hopkins, London School of Hygiene and Tropical Medicine (LSHTM), CDC, Médecins Sans Frontières.
• Databases
  WHO Global Health Observatory, UNICEF Immunization Dashboard, Gavi data portal, Global Health Data Exchange (GHDx), World Bank HealthStats, Open WHO, UN Comtrade.
• Magazines
  FiercePharma, Pharmaceutical Technology, PharmaVoice, BioPharma Dive, Vaccine Nation, PharmaTimes.
• Journals
  Vaccine, The Lancet Infectious Diseases, PLOS Neglected Tropical Diseases, Journal of Infectious Diseases, International Journal of Infectious Diseases, Bulletin of the World Health Organization.
• Newspapers
  The New York Times, The Guardian, Devex, Reuters Health, Nature News, Stat News.
• Associations
  World Health Organization (WHO), Gavi, UNICEF, International Vaccine Institute (IVI), PATH, Centers for Disease Control and Prevention (CDC), Global Task Force on Cholera Control (GTFCC), Médecins Sans Frontières, Coalition for Epidemic Preparedness Innovations (CEPI).
• Proprietary Elements
  CMI Data Analytics Tool, Proprietary CMI Existing Repository of information for last 8 years

*Definition: Cholera is an infectious disease caused by the bacterium Vibrio cholerae. It is typically spread through contaminated water and can cause severe diarrhea and dehydration, potentially leading to death if untreated. A vaccine for cholera can provide protection against this disease.